Subjects -> BIOLOGY (Total: 3174 journals)
    - BIOCHEMISTRY (239 journals)
    - BIOENGINEERING (143 journals)
    - BIOLOGY (1491 journals)
    - BIOPHYSICS (53 journals)
    - BIOTECHNOLOGY (243 journals)
    - BOTANY (233 journals)
    - CYTOLOGY AND HISTOLOGY (32 journals)
    - ENTOMOLOGY (67 journals)
    - GENETICS (165 journals)
    - MICROBIOLOGY (279 journals)
    - MICROSCOPY (13 journals)
    - ORNITHOLOGY (26 journals)
    - PHYSIOLOGY (73 journals)
    - ZOOLOGY (117 journals)

BIOLOGY (1491 journals)                  1 2 3 4 5 6 7 8 | Last

Showing 1 - 200 of 1720 Journals sorted alphabetically
AAPS Journal     Hybrid Journal   (Followers: 24)
Abasyn Journal of Life Sciences     Open Access   (Followers: 2)
ACS Pharmacology & Translational Science     Hybrid Journal   (Followers: 3)
ACS Synthetic Biology     Hybrid Journal   (Followers: 30)
Acta Biologica Hungarica     Full-text available via subscription   (Followers: 5)
Acta Biologica Marisiensis     Open Access  
Acta Biologica Sibirica     Open Access   (Followers: 1)
Acta Biologica Turcica     Open Access   (Followers: 1)
Acta Biomaterialia     Hybrid Journal   (Followers: 31)
Acta Biotheoretica     Hybrid Journal   (Followers: 3)
Acta Chiropterologica     Full-text available via subscription   (Followers: 5)
acta ethologica     Hybrid Journal   (Followers: 5)
Acta Fytotechnica et Zootechnica     Open Access   (Followers: 2)
Acta Ichthyologica et Piscatoria     Open Access   (Followers: 4)
Acta Médica Costarricense     Open Access   (Followers: 2)
Acta Musei Silesiae, Scientiae Naturales     Open Access  
Acta Neurobiologiae Experimentalis     Open Access  
Acta Scientiae Biological Research     Open Access   (Followers: 1)
Acta Scientiarum. Biological Sciences     Open Access   (Followers: 2)
Acta Scientifica Naturalis     Open Access   (Followers: 2)
Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis     Open Access   (Followers: 2)
Acta Universitatis Lodziensis : Folia Biologica et Oecologica     Open Access  
Actualidades Biológicas     Open Access   (Followers: 1)
Advanced Biology     Hybrid Journal   (Followers: 1)
Advanced Health Care Technologies     Open Access   (Followers: 12)
Advanced Journal of Graduate Research     Open Access   (Followers: 1)
Advanced Membranes     Open Access   (Followers: 3)
Advanced Quantum Technologies     Hybrid Journal   (Followers: 3)
Advances in Bioinformatics     Open Access   (Followers: 21)
Advances in Biological Regulation     Hybrid Journal   (Followers: 4)
Advances in Biology     Open Access   (Followers: 10)
Advances in Biomarker Sciences and Technology     Open Access   (Followers: 2)
Advances in Biosensors and Bioelectronics     Open Access   (Followers: 6)
Advances in Cell Biology/ Medical Journal of Cell Biology     Open Access   (Followers: 22)
Advances in Ecological Research     Full-text available via subscription   (Followers: 42)
Advances in Environmental Sciences - International Journal of the Bioflux Society     Open Access   (Followers: 14)
Advances in Enzyme Research     Open Access   (Followers: 10)
Advances in High Energy Physics     Open Access   (Followers: 23)
Advances in Human Biology     Open Access   (Followers: 6)
Advances in Life Science and Technology     Open Access   (Followers: 10)
Advances in Life Sciences     Open Access   (Followers: 5)
Advances in Marine Biology     Full-text available via subscription   (Followers: 23)
Advances in Tropical Biodiversity and Environmental Sciences     Open Access   (Followers: 4)
Advances in Virus Research     Full-text available via subscription   (Followers: 7)
Adversity and Resilience Science : Journal of Research and Practice     Hybrid Journal   (Followers: 3)
African Journal of Ecology     Hybrid Journal   (Followers: 17)
African Journal of Range & Forage Science     Hybrid Journal   (Followers: 12)
AFRREV STECH : An International Journal of Science and Technology     Open Access   (Followers: 3)
Ageing Research Reviews     Hybrid Journal   (Followers: 13)
Aggregate     Open Access   (Followers: 1)
Aging Cell     Open Access   (Followers: 23)
Agrokémia és Talajtan     Full-text available via subscription   (Followers: 2)
AJP Cell Physiology     Hybrid Journal   (Followers: 14)
AJP Endocrinology and Metabolism     Hybrid Journal   (Followers: 25)
AJP Lung Cellular and Molecular Physiology     Hybrid Journal   (Followers: 3)
Al-Kauniyah : Jurnal Biologi     Open Access  
Alasbimn Journal     Open Access   (Followers: 1)
Alces : A Journal Devoted to the Biology and Management of Moose     Open Access  
All Life     Open Access  
AMB Express     Open Access   (Followers: 1)
Ambix     Hybrid Journal   (Followers: 3)
American Journal of Agricultural and Biological Sciences     Open Access   (Followers: 6)
American Journal of Bioethics     Hybrid Journal   (Followers: 18)
American Journal of Human Biology     Hybrid Journal   (Followers: 15)
American Journal of Medical and Biological Research     Open Access   (Followers: 3)
American Journal of Plant Sciences     Open Access   (Followers: 19)
American Journal of Primatology     Hybrid Journal   (Followers: 15)
American Naturalist     Full-text available via subscription   (Followers: 78)
Amphibia-Reptilia     Hybrid Journal   (Followers: 4)
Anaerobe     Hybrid Journal   (Followers: 3)
Analytical Methods     Hybrid Journal   (Followers: 8)
Analytical Science Advances     Open Access   (Followers: 1)
Anatomical Science International     Hybrid Journal   (Followers: 3)
Animal Cells and Systems     Hybrid Journal   (Followers: 6)
Animal Microbiome     Open Access   (Followers: 1)
Animal Models and Experimental Medicine     Open Access  
Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale     Full-text available via subscription   (Followers: 2)
Annales Henri Poincaré     Hybrid Journal   (Followers: 2)
Annales Universitatis Mariae Curie-Sklodowska, sectio C – Biologia     Open Access   (Followers: 1)
Annals of Applied Biology     Hybrid Journal   (Followers: 6)
Annals of Biomedical Engineering     Hybrid Journal   (Followers: 18)
Annals of Human Biology     Hybrid Journal   (Followers: 5)
Annals of Science and Technology     Open Access   (Followers: 2)
Annual Research & Review in Biology     Open Access  
Annual Review of Biomedical Engineering     Full-text available via subscription   (Followers: 18)
Annual Review of Biophysics     Full-text available via subscription   (Followers: 24)
Annual Review of Cancer Biology     Full-text available via subscription   (Followers: 3)
Annual Review of Cell and Developmental Biology     Full-text available via subscription   (Followers: 41)
Annual Review of Food Science and Technology     Full-text available via subscription   (Followers: 13)
Annual Review of Genomics and Human Genetics     Full-text available via subscription   (Followers: 27)
Annual Review of Phytopathology     Full-text available via subscription   (Followers: 11)
Anthropological Review     Open Access   (Followers: 27)
Antibiotics     Open Access   (Followers: 10)
Antioxidants     Open Access   (Followers: 4)
Antioxidants & Redox Signaling     Hybrid Journal   (Followers: 8)
Antonie van Leeuwenhoek     Hybrid Journal   (Followers: 3)
Anzeiger für Schädlingskunde     Hybrid Journal   (Followers: 1)
Apidologie     Hybrid Journal   (Followers: 4)
Apmis     Hybrid Journal   (Followers: 1)
APOPTOSIS     Hybrid Journal   (Followers: 8)
Applied Biology     Open Access   (Followers: 1)
Applied Bionics and Biomechanics     Open Access   (Followers: 4)
Applied Phycology     Open Access  
Applied Vegetation Science     Full-text available via subscription   (Followers: 9)
Aquaculture Environment Interactions     Open Access   (Followers: 6)
Aquaculture International     Hybrid Journal   (Followers: 24)
Aquaculture Reports     Open Access   (Followers: 3)
Aquaculture, Aquarium, Conservation & Legislation - International Journal of the Bioflux Society     Open Access   (Followers: 8)
Aquatic Biology     Open Access   (Followers: 8)
Aquatic Ecology     Hybrid Journal   (Followers: 41)
Aquatic Ecosystem Health & Management     Hybrid Journal   (Followers: 15)
Aquatic Science and Technology     Open Access   (Followers: 2)
Aquatic Toxicology     Hybrid Journal   (Followers: 25)
Arabian Journal of Scientific Research / المجلة العربية للبحث العلمي     Open Access  
Archaea     Open Access   (Followers: 3)
Archiv für Molluskenkunde: International Journal of Malacology     Full-text available via subscription   (Followers: 1)
Archives of Biological Sciences     Open Access  
Archives of Microbiology     Hybrid Journal   (Followers: 9)
Archives of Natural History     Hybrid Journal   (Followers: 7)
Archives of Oral Biology     Hybrid Journal   (Followers: 2)
Archives of Virology     Hybrid Journal   (Followers: 6)
Archivum Immunologiae et Therapiae Experimentalis     Hybrid Journal   (Followers: 2)
Arctic     Open Access   (Followers: 1)
Arid Ecosystems     Hybrid Journal   (Followers: 2)
Arquivos do Museu Dinâmico Interdisciplinar     Open Access  
Arthropod Structure & Development     Hybrid Journal   (Followers: 2)
Arthropod Systematics & Phylogeny     Open Access   (Followers: 2)
Artificial DNA: PNA & XNA     Hybrid Journal   (Followers: 2)
Artificial Intelligence in the Life Sciences     Open Access  
Asian Bioethics Review     Full-text available via subscription   (Followers: 2)
Asian Journal of Biological Sciences     Open Access   (Followers: 2)
Asian Journal of Biology     Open Access  
Asian Journal of Biotechnology and Bioresource Technology     Open Access  
Asian Journal of Cell Biology     Open Access   (Followers: 4)
Asian Journal of Developmental Biology     Open Access   (Followers: 1)
Asian Journal of Medical and Biological Research     Open Access   (Followers: 3)
Asian Journal of Nematology     Open Access   (Followers: 4)
Asian Journal of Poultry Science     Open Access   (Followers: 3)
Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche     Open Access  
Australian Life Scientist     Full-text available via subscription   (Followers: 2)
Australian Mammalogy     Hybrid Journal   (Followers: 8)
Autophagy     Hybrid Journal   (Followers: 7)
Avian Biology Research     Hybrid Journal   (Followers: 4)
Avian Conservation and Ecology     Open Access   (Followers: 16)
Bacterial Empire     Open Access   (Followers: 1)
Bacteriology Journal     Open Access   (Followers: 2)
Bacteriophage     Full-text available via subscription   (Followers: 2)
Bangladesh Journal of Bioethics     Open Access  
Bangladesh Journal of Plant Taxonomy     Open Access  
Bangladesh Journal of Scientific Research     Open Access  
Berita Biologi     Open Access  
Between the Species     Open Access   (Followers: 2)
BIO Web of Conferences     Open Access  
Bio-Grafía. Escritos sobre la Biología y su enseñanza     Open Access  
Bio-Lectura     Open Access  
BIO-SITE : Biologi dan Sains Terapan     Open Access  
Bioactive Compounds in Health and Disease     Open Access  
Biocatalysis and Biotransformation     Hybrid Journal   (Followers: 5)
BioCentury Innovations     Full-text available via subscription   (Followers: 2)
Biochemistry and Cell Biology     Hybrid Journal   (Followers: 17)
Biochimie     Hybrid Journal   (Followers: 4)
BioControl     Hybrid Journal   (Followers: 2)
Biocontrol Science and Technology     Hybrid Journal   (Followers: 5)
Biodemography and Social Biology     Hybrid Journal  
BIODIK : Jurnal Ilmiah Pendidikan Biologi     Open Access  
BioDiscovery     Open Access   (Followers: 2)
Biodiversitas : Journal of Biological Diversity     Open Access   (Followers: 1)
Biodiversity : Research and Conservation     Open Access   (Followers: 28)
Biodiversity Data Journal     Open Access   (Followers: 7)
Biodiversity Informatics     Open Access   (Followers: 2)
Biodiversity Information Science and Standards     Open Access   (Followers: 1)
Bioeduscience     Open Access  
Bioeksperimen : Jurnal Penelitian Biologi     Open Access  
Bioelectrochemistry     Hybrid Journal   (Followers: 1)
Bioelectromagnetics     Hybrid Journal   (Followers: 1)
Bioenergy Research     Hybrid Journal   (Followers: 3)
Bioengineering and Bioscience     Open Access   (Followers: 1)
BioEssays     Hybrid Journal   (Followers: 10)
Bioethica     Open Access   (Followers: 1)
Bioethics     Hybrid Journal   (Followers: 21)
BioéthiqueOnline     Open Access   (Followers: 1)
Biogeographia : The Journal of Integrative Biogeography     Open Access   (Followers: 2)
Biogeosciences (BG)     Open Access   (Followers: 14)
Biogeosciences Discussions (BGD)     Open Access   (Followers: 4)
Bioinformatics     Hybrid Journal   (Followers: 216)
Bioinformatics Advances : Journal of the International Society for Computational Biology     Open Access   (Followers: 1)
Bioinformatics and Biology Insights     Open Access   (Followers: 13)
Biointerphases     Open Access   (Followers: 1)
Biojournal of Science and Technology     Open Access  
BioLink : Jurnal Biologi Lingkungan, Industri, Kesehatan     Open Access  
Biologia     Hybrid Journal   (Followers: 1)
Biologia Futura     Hybrid Journal  
Biologia on-line : Revista de divulgació de la Facultat de Biologia     Open Access  
Biological Bulletin     Partially Free   (Followers: 6)
Biological Control     Hybrid Journal   (Followers: 6)
Biological Invasions     Hybrid Journal   (Followers: 22)
Biological Journal of the Linnean Society     Hybrid Journal   (Followers: 19)
Biological Procedures Online     Open Access  
Biological Psychiatry     Hybrid Journal   (Followers: 52)
Biological Psychology     Hybrid Journal   (Followers: 5)

        1 2 3 4 5 6 7 8 | Last

Similar Journals
Journal Cover
BioCentury Innovations
Number of Followers: 2  
 
  Full-text available via subscription Subscription journal
ISSN (Online) 2377-3030
Published by BioCentury Homepage  [1 journal]
  • Senate user fee bill seeks diagnostics revamp

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 6:12 PM PDT BIOCENTURY POLITICS, POLICY & LAWSENATE USER FEE BILL SEEKS DIAGNOSTICS REVAMPBY HELP Committee includes VALID Act in user fee discussion drafthttps://www.biocentury.com/article/643669/senate-user-fee-bill-seeks-diagnostics-revamp© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 18:12:01 -070
       
  • Bio€quity Europe recap, part 1: talent & dealmaking

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 5:59 PM PDT BIOCENTURY DEALSBIO€QUITY EUROPE RECAP, PART 1: TALENT & DEALMAKINGBY Medicxi’s Francesco De Rubertis, MSD’s Khatereh Ahmadi discuss the global hunt for talent and quality assetshttps://www.biocentury.com/article/643667/bio-quity-europe-recap-part-1-talent-dealmaking© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 17:59:24 -070
       
  • May 17 Quick Takes: Abeona licenses gene therapy to Ultragenyx

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 5:57 PM PDT BIOCENTURY DEALSMAY 17 QUICK TAKES: ABEONA LICENSES GENE THERAPY TO ULTRAGENYXBY Plus Evotec, Sernova partner in diabetes and updates from Mirvie, Cytokinetics, Kallyope, Sosei and morehttps://www.biocentury.com/article/643658/may-17-quick-takes-abeona-licenses-gene-therapy-to-ultragenyx© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 17:57:42 -070
       
  • Fromen to leave PacBio as CCO

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 5:39 PM PDT BIOCENTURY MANAGEMENT TRACKSFROMEN TO LEAVE PACBIO AS CCOBY Plus Vraniak joins Inversago as CFO and updates from Thabor, Glympse, Civetta and morehttps://www.biocentury.com/article/643660/fromen-to-leave-pacbio-as-cco© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 17:39:31 -070
       
  • Atlas-backed Remix adds $70M series B, building on J&J deal

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 4:34 PM PDT BIOCENTURY FINANCEATLAS-BACKED REMIX ADDS $70M SERIES B, BUILDING ON J&J DEALBY RNA processing company could reveal pipeline candidates this yearhttps://www.biocentury.com/article/643652/atlas-backed-remix-adds-70m-series-b-building-on-j-j-deal© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 16:34:01 -070
       
  • FDA wants more data for common antidepressant to treat COVID-19 

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 4:28 PM PDT BIOCENTURY REGULATIONFDA WANTS MORE DATA FOR COMMON ANTIDEPRESSANT TO TREAT COVID-19 BY Fluvoxamine trial hits endpoint but FDA not persuaded  https://www.biocentury.com/article/643641/fda-wants-more-data-for-common-antidepressant-to-treat-covid-19© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 16:28:22 -070
       
  • Indaco adds to Italian ecosystem with launch of first dedicated biotech
           fund

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 7:47 AM PDT BIOCENTURY FINANCEINDACO ADDS TO ITALIAN ECOSYSTEM WITH LAUNCH OF FIRST DEDICATED BIOTECH FUNDBY Firm raises €95M at first close, with €150M target for Italian biotechshttps://www.biocentury.com/article/643650/indaco-adds-to-italian-ecosystem-with-launch-of-first-dedicated-biotech-fund© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 07:47:49 -070
       
  • FDA bolstering rare disease oversight

    • Free pre-print version: Loading...

      Abstract: MAY 17, 2022 6:21 AM PDT BIOCENTURY POLITICS, POLICY & LAWFDA BOLSTERING RARE DISEASE OVERSIGHTBY Advocates pressing for more, including center of excellencehttps://www.biocentury.com/article/643634/fda-bolstering-rare-disease-oversight© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 17 May 2022 06:21:25 -070
       
  • Sofinnova Partners’ growth deal, plus BioCentury’s Distillery
           on tap

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 6:33 PM PDT BIOCENTURY DEALSSOFINNOVA PARTNERS’ GROWTH DEAL, PLUS BIOCENTURY’S DISTILLERY ON TAPBY Plus: Caribou’s clinical data and how biopharmas are weighing their commitment to Russian patientshttps://www.biocentury.com/article/643643/sofinnova-partners-growth-deal-plus-biocentury-s-distillery-on-tap© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 18:33:33 -070
       
  • CRISPR, Nkarta join flurry of CMO moves

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 6:33 PM PDT BIOCENTURY MANAGEMENT TRACKSCRISPR, NKARTA JOIN FLURRY OF CMO MOVESBY Siegall leaving Seagen amid concerns over conduct; new CFO at Mirati and morehttps://www.biocentury.com/article/643633/crispr-nkarta-join-flurry-of-cmo-moves© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 18:33:31 -070
       
  • Lurie winners’ epigenetic view into the biology of aging diseases

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 5:31 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONLURIE WINNERS’ EPIGENETIC VIEW INTO THE BIOLOGY OF AGING DISEASESBY Anne Brunet and Andrew Dillin’s multispecies research highlights epigenetic and mitochondrial biology that could underlie constellations of diseaseshttps://www.biocentury.com/article/643601/lurie-winners-epigenetic-view-into-the-biology-of-aging-diseases© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 17:31:10 -070
       
  • Kriya bulking up gene therapy R&D, infrastructure with $270M C round

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 5:13 PM PDT BIOCENTURY FINANCEKRIYA BULKING UP GENE THERAPY R&D, INFRASTRUCTURE WITH $270M C ROUNDBY Since last year’s $100M series B, Kriya has hired a CFO, presidents for oncology, ophthalmology and rare diseaseshttps://www.biocentury.com/article/643637/kriya-bulking-up-gene-therapy-r-d-infrastructure-with-270m-c-round© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 17:13:04 -070
       
  • Cugene strikes $48.5M AbbVie deal as cancer pipeline nears clinic

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 5:06 PM PDT BIOCENTURY DEALSCUGENE STRIKES $48.5M ABBVIE DEAL AS CANCER PIPELINE NEARS CLINICBY Massachusetts start-up partners clinical, IL-2-targeting autoimmune program as it preps series of INDs in oncologyhttps://www.biocentury.com/article/643631/cugene-strikes-48-5m-abbvie-deal-as-cancer-pipeline-nears-clinic© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 17:06:27 -070
       
  • Where European biotechs sourced C-suite hires in 2021

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 4:59 PM PDT BIOCENTURY DATA BYTEWHERE EUROPEAN BIOTECHS SOURCED C-SUITE HIRES IN 2021BY Public biotechs were the main suppliers of C-suite talent to both private and public European biotechs in 2021https://www.biocentury.com/article/643609/where-european-biotechs-sourced-c-suite-hires-in-2021© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 16:59:02 -070
       
  • May 16 Quick Takes: Agios again narrows focus

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 4:54 PM PDT BIOCENTURY DEALSMAY 16 QUICK TAKES: AGIOS AGAIN NARROWS FOCUSBY Plus Shionogi-F2G, Chimerix, Travere, Valneva and morehttps://www.biocentury.com/article/643629/may-16-quick-takes-agios-again-narrows-focus© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 16:54:46 -070
       
  • Sofinnova Partners seeks growth, independence in minority stake sale to
           Apollo

    • Free pre-print version: Loading...

      Abstract: MAY 16, 2022 5:01 AM PDT BIOCENTURY FINANCESOFINNOVA PARTNERS SEEKS GROWTH, INDEPENDENCE IN MINORITY STAKE SALE TO APOLLOBY PE firm commits up to €1B to future funds, while European VC gains access to broader LP base, structured financing instrumentshttps://www.biocentury.com/article/643627/sofinnova-partners-seeks-growth-independence-in-minority-stake-sale-to-apollo© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 16 May 2022 05:01:12 -070
       
  • Human Cell Atlas takes major step toward defining cellular diversity of
           human tissues

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 5:38 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONHUMAN CELL ATLAS TAKES MAJOR STEP TOWARD DEFINING CELLULAR DIVERSITY OF HUMAN TISSUESBY Four https://www.biocentury.com/article/643625/human-cell-atlas-takes-major-step-toward-defining-cellular-diversity-of-human-tissues© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 17:38:43 -070
       
  • Cherrington to be chair at Actym, Stutz joins as CBO

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 5:02 PM PDT BIOCENTURY MANAGEMENT TRACKSCHERRINGTON TO BE CHAIR AT ACTYM, STUTZ JOINS AS CBOBY Plus Krishnan leaves Arcus and updates from Invectys, Sawai and Westhttps://www.biocentury.com/article/643613/cherrington-to-be-chair-at-actym-stutz-joins-as-cbo© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 17:02:31 -070
       
  • May 13 Quick Takes: China proposes exclusivity for orphan, pediatric drugs

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 4:52 PM PDT BIOCENTURY REGULATIONMAY 13 QUICK TAKES: CHINA PROPOSES EXCLUSIVITY FOR ORPHAN, PEDIATRIC DRUGSBY Plus FDA approves Lilly’s Mounjaro, Akebia loses partner, UCB psoriasis candidate hits FDA snag, and updates from Mitsubishi, BridgeBio and morehttps://www.biocentury.com/article/643597/may-13-quick-takes-china-proposes-exclusivity-for-orphan-pediatric-drugs© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 16:52:42 -070
       
  • Aro’s protein-siRNA conjugate for Pompe disease; plus Rheos, Mozart
           and more

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 4:33 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONARO’S PROTEIN-SIRNA CONJUGATE FOR POMPE DISEASE; PLUS RHEOS, MOZART AND MOREBY BioCentury’s roundup of translational newshttps://www.biocentury.com/article/643603/aro-s-protein-sirna-conjugate-for-pompe-disease-plus-rheos-mozart-and-more© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 16:33:00 -070
       
  • Italy solves its biotech chicken-and-egg problem

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 3:16 PM PDT BIOCENTURY FINANCEITALY SOLVES ITS BIOTECH CHICKEN-AND-EGG PROBLEM BY New funds and infrastructure to support company creation in Italy could in turn attract more investors and entrepreneurshttps://www.biocentury.com/article/643586/italy-solves-its-biotech-chicken-and-egg-problem© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 15:16:31 -070
       
  • Cartesian expanding therapeutic window, disease settings for CAR T

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 2:58 PM PDT BIOCENTURY EMERGING COMPANY PROFILECARTESIAN EXPANDING THERAPEUTIC WINDOW, DISEASE SETTINGS FOR CAR TBY CAR T therapy for myasthenia gravis shows strong efficacy, though questions remain about durabilityhttps://www.biocentury.com/article/643607/cartesian-expanding-therapeutic-window-disease-settings-for-car-t© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 14:58:29 -070
       
  • In latest Italy deal, Sofinnova seeds nanodelivery start-up NanoPhoria
           with €3.5M

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 11:36 AM PDT BIOCENTURY FINANCEIN LATEST ITALY DEAL, SOFINNOVA SEEDS NANODELIVERY START-UP NANOPHORIA WITH €3.5MBY Targeted, non-viral drug delivery start-up is eighth deal for European firm’s Italy-focused Telethon Fundhttps://www.biocentury.com/article/643605/in-latest-italy-deal-sofinnova-seeds-nanodelivery-start-up-nanophoria-with-3-5m© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 11:36:28 -070
       
  • DeciBio’s VC arm aims to further parent consultancy’s mission

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 11:18 AM PDT BIOCENTURY FINANCEDECIBIO’S VC ARM AIMS TO FURTHER PARENT CONSULTANCY’S MISSIONBY Targeting smaller precision medicine companies, Los Angeles firm making cash investments, turning consulting services into equityhttps://www.biocentury.com/article/642953/decibio-s-vc-arm-aims-to-further-parent-consultancy-s-mission© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 11:18:24 -070
       
  • Nuvig: bringing immune homeostasis to inflammatory disease with a $47M A
           round

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 10:08 AM PDT BIOCENTURY EMERGING COMPANY PROFILENUVIG: BRINGING IMMUNE HOMEOSTASIS TO INFLAMMATORY DISEASE WITH A $47M A ROUNDBY Backed by Novo Holdings and Platanus, Nuvig is designing proteins to selectively suppress active immune pathwayshttps://www.biocentury.com/article/643550/nuvig-bringing-immune-homeostasis-to-inflammatory-disease-with-a-47m-a-round© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 10:08:55 -070
       
  • Distillery spotlight on Italian innovation

    • Free pre-print version: Loading...

      Abstract: MAY 13, 2022 10:04 AM PDT BIOCENTURY DATA BYTEDISTILLERY SPOTLIGHT ON ITALIAN INNOVATIONBY Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company foundershttps://www.biocentury.com/article/643567/distillery-spotlight-on-italian-innovation© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Fri, 13 May 2022 10:04:34 -070
       
  • New CEOs at CorMedix, Medigene

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 5:24 PM PDT BIOCENTURY MANAGEMENT TRACKSNEW CEOS AT CORMEDIX, MEDIGENEBY Plus updates from Elicio, Rejuvenate, Canbridge and morehttps://www.biocentury.com/article/643594/new-ceos-at-cormedix-medigene© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 17:24:29 -070
       
  • The road to Bio€quity Europe: navigating through talent &
           capital headwinds

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 4:06 PM PDT BIOCENTURY PRODUCT DEVELOPMENTTHE ROAD TO BIO€QUITY EUROPE: NAVIGATING THROUGH TALENT & CAPITAL HEADWINDSBY Why Italy is now better placed to survive the talent, capital crunchhttps://www.biocentury.com/article/643576/the-road-to-bio-quity-europe-navigating-through-talent-capital-headwinds© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 16:06:27 -070
       
  • CRISPR Therapeutics advances CAR T modality in T cell cancers

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 4:04 PM PDT BIOCENTURY PRODUCT DEVELOPMENTCRISPR THERAPEUTICS ADVANCES CAR T MODALITY IN T CELL CANCERSBY CRISPR-edited CAR T CTX130 generates responses in challenging T cell lymphoma indicationshttps://www.biocentury.com/article/643587/crispr-therapeutics-advances-car-t-modality-in-t-cell-cancers© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 16:04:30 -070
       
  • NIH’s vaccines and diagnostics now fill WHO’s COVID-19
           tech pool

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 3:30 PM PDT BIOCENTURY DEALSNIH’S VACCINES AND DIAGNOSTICS NOW FILL WHO’S COVID-19 TECH POOLBY NIH has quadrupled the pool’s technologies and secured it trifecta of countermeasure types: vaccines, antivirals and diagnosticshttps://www.biocentury.com/article/643591/nih-s-vaccines-and-diagnostics-now-fill-who-s-covid-19-tech-pool© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 15:30:42 -070
       
  • Biopharma companies facing tough decisions in Russia

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 2:22 PM PDT BIOCENTURY POLITICS, POLICY & LAWBIOPHARMA COMPANIES FACING TOUGH DECISIONS IN RUSSIABY Pharmaceutical companies balancing calls to disengage vs. duties to patientshttps://www.biocentury.com/article/643554/biopharma-companies-facing-tough-decisions-in-russia© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 14:22:34 -070
       
  • Russia boycott includes CAR T therapies

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 2:18 PM PDT BIOCENTURY POLITICS, POLICY & LAWRUSSIA BOYCOTT INCLUDES CAR T THERAPIESBY Behind Miltenyi Biotec’s decision to stop sales of vectors for CAR T therapy to Russia to protest warhttps://www.biocentury.com/article/643564/russia-boycott-includes-car-t-therapies© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 14:18:26 -070
       
  • BMS gains license to BridgeBio’s SHP-2, already in deal for Opdivo
           combo

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 1:24 PM PDT BIOCENTURY DEALSBMS GAINS LICENSE TO BRIDGEBIO’S SHP-2, ALREADY IN DEAL FOR OPDIVO COMBOBY Pharma pays $90M up front for rights to small molecule that could become a once-daily option in combinations for some cancershttps://www.biocentury.com/article/643590/bms-gains-license-to-bridgebio-s-shp-2-already-in-deal-for-opdivo-combo© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 13:24:25 -070
       
  • CRISPR shines in another application with Caribou’s first CAR T data

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 7:14 AM PDT BIOCENTURY PRODUCT DEVELOPMENTCRISPR SHINES IN ANOTHER APPLICATION WITH CARIBOU’S FIRST CAR T DATABY Caribou’s first clinical data suggest PD-1 knockout may drive up allogeneic CAR T efficacy, durabilityhttps://www.biocentury.com/article/643581/crispr-shines-in-another-application-with-caribou-s-first-car-t-data© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 07:14:36 -070
       
  • Cullinan gets $275M up front, reshapes deal with Taiho for EGFR program

    • Free pre-print version: Loading...

      Abstract: MAY 12, 2022 7:04 AM PDT BIOCENTURY DEALSCULLINAN GETS $275M UP FRONT, RESHAPES DEAL WITH TAIHO FOR EGFR PROGRAMBY Three years after sourcing targeted cancer program from Japanese pharma, Cullinan sells back subsidiary while retaining upsidehttps://www.biocentury.com/article/643584/cullinan-gets-275m-up-front-reshapes-deal-with-taiho-for-egfr-program© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Thu, 12 May 2022 07:04:32 -070
       
  • Siegall resigns as Umoja chair

    • Free pre-print version: Loading...

      Abstract: MAY 11, 2022 6:36 PM PDT BIOCENTURY MANAGEMENT TRACKSSIEGALL RESIGNS AS UMOJA CHAIRBY Plus short stay for new Moderna CFO and updates from CSL Plasma, Spectrum, Pharvaris, Xequel and morehttps://www.biocentury.com/article/643561/siegall-resigns-as-umoja-chair© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 11 May 2022 18:36:28 -070
       
  • May 11 Quick Takes: BMS extends protein degradation partnership with
           Evotec

    • Free pre-print version: Loading...

      Abstract: MAY 11, 2022 6:29 PM PDT BIOCENTURY DEALSMAY 11 QUICK TAKES: BMS EXTENDS PROTEIN DEGRADATION PARTNERSHIP WITH EVOTECBY Plus: Delay for Amicus’ Pompe therapy, and updates from Artax, Cortexyme and morehttps://www.biocentury.com/article/643563/may-11-quick-takes-bms-extends-protein-degradation-partnership-with-evotec© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 11 May 2022 18:29:33 -070
       
  • Interpreting FDA decisions on China-only data packages

    • Free pre-print version: Loading...

      Abstract: MAY 11, 2022 1:55 PM PDT BIOCENTURY REGULATIONINTERPRETING FDA DECISIONS ON CHINA-ONLY DATA PACKAGESBY Rare U.S. cancers could still be in play for China-only data, but the surest path is global trials whenever possiblehttps://www.biocentury.com/article/643457/interpreting-fda-decisions-on-china-only-data-packages© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 11 May 2022 13:55:12 -070
       
  • TIGIT frenzy doesn’t end with Roche’s Phase III miss

    • Free pre-print version: Loading...

      Abstract: MAY 11, 2022 11:42 AM PDT BIOCENTURY PRODUCT DEVELOPMENTTIGIT FRENZY DOESN’T END WITH ROCHE’S PHASE III MISSBY Tiragolumab miss is a major blow, but differentiated blockers against the target fill the pipelinehttps://www.biocentury.com/article/643559/tigit-frenzy-doesn-t-end-with-roche-s-phase-iii-miss© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Wed, 11 May 2022 11:42:32 -070
       
  • May 10 Quick Takes: ‘molecular machines’ company MOMA lands
           $150M series B

    • Free pre-print version: Loading...

      Abstract: MAY 10, 2022 5:57 PM PDT BIOCENTURY PRODUCT DEVELOPMENTMAY 10 QUICK TAKES: ‘MOLECULAR MACHINES’ COMPANY MOMA LANDS $150M SERIES BBY Plus GPCR play Domain raises $42M and updates from OncoHost, Eisai, UCB, Idorsia and morehttps://www.biocentury.com/article/643544/may-10-quick-takes-molecular-machines-company-moma-lands-150m-series-b© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 10 May 2022 17:57:44 -070
       
  • Pfizer’s Biohaven $11.6B takeout could fuel its spinout through the
           bear market

    • Free pre-print version: Loading...

      Abstract: MAY 10, 2022 5:50 PM PDT BIOCENTURY DEALSPFIZER’S BIOHAVEN $11.6B TAKEOUT COULD FUEL ITS SPINOUT THROUGH THE BEAR MARKETBY Pharma acquires leading position in the oral CGRP market through acquisitionhttps://www.biocentury.com/article/643542/pfizer-s-biohaven-11-6b-takeout-could-fuel-its-spinout-through-the-bear-market© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 10 May 2022 17:50:12 -070
       
  • Shea replacing Kim as CEO of Inovio

    • Free pre-print version: Loading...

      Abstract: MAY 10, 2022 5:47 PM PDT BIOCENTURY MANAGEMENT TRACKSSHEA REPLACING KIM AS CEO OF INOVIOBY Plus new chief commercial officer at DNA Script, and updates from Boston Pharma, Quantum SI, Beta, Longeveron and morehttps://www.biocentury.com/article/643541/shea-replacing-kim-as-ceo-of-inovio© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 10 May 2022 17:47:25 -070
       
  • Novo deal with Pioneering Medicines opens door to array of technologies

    • Free pre-print version: Loading...

      Abstract: MAY 10, 2022 5:17 PM PDT BIOCENTURY DEALSNOVO DEAL WITH PIONEERING MEDICINES OPENS DOOR TO ARRAY OF TECHNOLOGIESBY Deal with Danish pharma to give Flagship’s internal drug development team insights into large, chronic diseaseshttps://www.biocentury.com/article/643539/novo-deal-with-pioneering-medicines-opens-door-to-array-of-technologies© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 10 May 2022 17:17:44 -070
       
  • U.K. still queen of series A rounds

    • Free pre-print version: Loading...

      Abstract: MAY 10, 2022 5:14 PM PDT BIOCENTURY DATA BYTEU.K. STILL QUEEN OF SERIES A ROUNDSBY British biotechs raised over $1.1B of the total $3.8B series A financings in Europe in 2019-21https://www.biocentury.com/article/643547/u-k-still-queen-of-series-a-rounds© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 10 May 2022 17:14:11 -070
       
  • CARsgen leverages investigator-led study to advance solid tumor CAR T

    • Free pre-print version: Loading...

      Abstract: MAY 10, 2022 5:13 PM PDT BIOCENTURY PRODUCT DEVELOPMENTCARSGEN LEVERAGES INVESTIGATOR-LED STUDY TO ADVANCE SOLID TUMOR CAR TBY Durability, relapse questions remain for the Claudin18.2 programhttps://www.biocentury.com/article/643548/carsgen-leverages-investigator-led-study-to-advance-solid-tumor-car-t© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Tue, 10 May 2022 17:13:47 -070
       
  • FDA reform on deck, plus translation at Howard: a BioCentury podcast

    • Free pre-print version: Loading...

      Abstract: MAY 09, 2022 5:34 PM PDT BIOCENTURY POLITICS, POLICY & LAWFDA REFORM ON DECK, PLUS TRANSLATION AT HOWARD: A BIOCENTURY PODCASTBY A House E&C deal sets the parameters for FDA reforms, including enhancing accelerated approval and improving clinical trial diversityhttps://www.biocentury.com/article/643532/fda-reform-on-deck-plus-translation-at-howard-a-biocentury-podcast© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 09 May 2022 17:34:25 -070
       
  • May 9 Quick Takes: Madrigal adds co-primary endpoint to NASH study

    • Free pre-print version: Loading...

      Abstract: MAY 09, 2022 5:30 PM PDT BIOCENTURY PRODUCT DEVELOPMENTMAY 9 QUICK TAKES: MADRIGAL ADDS CO-PRIMARY ENDPOINT TO NASH STUDYBY Plus first EU-listed life sciences SPAC launches and updates from Janssen, Myovant and morehttps://www.biocentury.com/article/643525/may-9-quick-takes-madrigal-adds-co-primary-endpoint-to-nash-study© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 09 May 2022 17:30:30 -070
       
  • Pheast: Forty Seven founders reunite for precision macrophage combos

    • Free pre-print version: Loading...

      Abstract: MAY 09, 2022 5:12 PM PDT BIOCENTURY EMERGING COMPANY PROFILEPHEAST: FORTY SEVEN FOUNDERS REUNITE FOR PRECISION MACROPHAGE COMBOSBY Backed by Catalio and Arch, start-up from Forty Seven founders aims to target patient-specific ‘don’t eat me’ signals beyond CD47https://www.biocentury.com/article/643322/pheast-forty-seven-founders-reunite-for-precision-macrophage-combos© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 09 May 2022 17:12:31 -070
       
  • CEO Siegall takes leave of absence at Seagen

    • Free pre-print version: Loading...

      Abstract: MAY 09, 2022 4:06 PM PDT BIOCENTURY MANAGEMENT TRACKSCEO SIEGALL TAKES LEAVE OF ABSENCE AT SEAGENBY Plus Martin stepping down as CEO of ADC and updates from https://www.biocentury.com/article/643529/ceo-siegall-takes-leave-of-absence-at-seagen© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 09 May 2022 16:06:30 -070
       
  • VCs back Aspen with $147.5M as neuron replacement therapy heads toward
           clinic

    • Free pre-print version: Loading...

      Abstract: MAY 09, 2022 2:04 PM PDT BIOCENTURY FINANCEVCS BACK ASPEN WITH $147.5M AS NEURON REPLACEMENT THERAPY HEADS TOWARD CLINICBY Tapping GV, Lyfe and Revelation as series B leaders, biotech sought deep-pocketed syndicate with long-term view to match series A backerhttps://www.biocentury.com/article/643527/vcs-back-aspen-with-147-5m-as-neuron-replacement-therapy-heads-toward-clinic© 2022 BioCentury Inc. All Rights Reserved
      PubDate: Mon, 09 May 2022 14:04:53 -070
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 3.236.50.252
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-